Results 101 to 110 of about 285,650 (298)
HPD is identified as an RNA‐binding protein that promotes mRNA translation by binding to RRACH motifs via its double‐stranded RNA‐binding domains. This RNA‐binding activity critically sustains glycolysis in ovarian cancer cells. Disrupting HPD's RNA‐binding function effectively suppresses tumor growth and enhances therapeutic sensitivity, highlighting ...
Fei Xie+21 more
wiley +1 more source
A Two-stage Theory of Carcinogenesis in Relation to the Age Distribution of Human Cancer
P. Armitage, Ronald J. Doll
openalex +2 more sources
Epidermal Transplantation during Chemical Carcinogenesis [PDF]
R. E. Billingham+2 more
openalex +1 more source
Inducing ferroptosis is a promising strategy for combating tumor resistance. Upregulated PIP5K1A competes with NRF2 for KEAP1 binding, which decreases the ubiquitination degradation of NRF2 and promotes its nuclear translocation, thereby suppressing ferroptosis, and ultimately driving hepatocellular carcinoma (HCC) tumorigeneses and sorafenib ...
Mengzhou Guo+9 more
wiley +1 more source
Effect of Choline on Experimental Carcinogenesis [PDF]
Julie Cook, R. Schoental
openalex +1 more source
Indole‐3‐acetic acid (3‐IAA) derived from gut P. distasonis binds to AhR in bladder cancer cells and downregulates FASN transcription, thereby increasing sensitivity to ferroptosis and suppressing the development of bladder tumors. Specifically, 3‐IAA treatment leads to an increase in the proportion of PC/PE‐PUFAs and a decrease in the proportions of ...
Weijia Li+16 more
wiley +1 more source
HiCGen introduces a hierarchical deep learning framework to predict genome organization across spatial scales using DNA sequences and genomic features. The model enables cross‐cell‐type predictions and in silico perturbation analysis, revealing correlations between loop domains and higher‐order structures.
Jiachen Wei, Yue Xue, Yi Qin Gao
wiley +1 more source
Ovarian cancer patients with high levels of mortalin protein in their tumors have worse survival. The investigational drug SHetA2 interferes with mortalin's support of mitochondria. The resulting mitochondrial damage causes a process called mitophagy that contributes to how SHetA2 kills cancer cells. Noncancerous cells repair their mitochondria through
Vishal Chandra+9 more
wiley +1 more source